|
|
Volumn 368, Issue 15, 2013, Pages 1458-1459
|
|
The authors reply
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABIRATERONE;
BISPHOSPHONIC ACID DERIVATIVE;
CYTOTOXIC AGENT;
DOCETAXEL;
OPIATE;
PREDNISOLONE;
PROSTATE SPECIFIC ANTIGEN;
ANDROSTANE DERIVATIVE;
ANTINEOPLASTIC AGENT;
PREDNISONE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PAIN;
CANCER PROGNOSIS;
CLINICAL ASSESSMENT;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG SAFETY;
HUMAN;
LETTER;
LONG TERM CARE;
METASTATIC CASTRATION RESISTANT PROSTATE CANCER;
MONOTHERAPY;
OSTEOPENIA;
OSTEOPOROSIS;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROSTATE CANCER;
RISK BENEFIT ANALYSIS;
TREATMENT DURATION;
MALE;
NOTE;
PROSTATE TUMOR;
ANDROSTADIENES;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
HUMANS;
MALE;
PREDNISONE;
PROSTATIC NEOPLASMS;
|
|
EID: 84875932058
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1301594 Document Type: Letter |
|
Times cited : (33)
|
|
References (4)
|
